The purpose of the Trial-Ready Cohort - Down Syndrome (TRC-DS) is to enroll 120 healthy adults with Down syndrome (DS), between the ages of 25-55, into a trial ready cohort (TRC), and up to 450 participants in total including co-enrolled in the Alzheimer Biomarkers Consortium - Down Syndrome (ABC-DS) study. Participants enrolled in the TRC-DS will undergo longitudinal cognitive and clinical assessment, genetic and biomarker testing, as well as imaging and biospecimen collection. Using these outcome measures, researchers will analyze the relationships between cognitive measures and biomarkers of Alzheimer's disease (AD) to identify endpoints for AD clinical trials in DS that best reflect disease progression. To learn more about the study and participating sites, visit our study website at: https://www.trcds.org/. TRC-DS is collaborating with the Alzheimer's Disease Biomarker Consortium-Down Syndrome (ABC-DS) to allow study participants to be concurrently enrolled in both ABC-DS and TRC-DS, referred to as "co-enrollment". ABC-DS is a longitudinal, observational research study that is overseen at University of Pittsburgh Coordinating Center. ABC-DS participants who express interest in potentially joining a clinical trial in the future and who meet TRC-DS eligibility criteria, may choose to co-enroll in TRC-DS at an ABC-DS Site. Co-enrolled participants will adhere to the ABC-DS protocol and schedule of activities, but agree to share their data with the TRC-DS team and to receive invitations for future participation in clinical trials. Fore more information on ABC-DS please visit https://www.nia.nih.gov/research/abc-ds or http://abcds.pitt.edu/.
Study Type
OBSERVATIONAL
Enrollment
450
Barrow Neurological Institute
Phoenix, Arizona, United States
RECRUITINGUniversity of California, Irvine School of Medicine, Co-Enrolling through ABC-DS Only
Orange, California, United States
RECRUITINGLinda Crnic Institute for Down Syndrome, University of Colorado
Aurora, Colorado, United States
RECRUITINGAdvocate Medical Group Adult Down Syndrome Center
Park Ridge, Illinois, United States
NOT_YET_RECRUITINGIndiana University
Indianapolis, Indiana, United States
RECRUITINGUniversity of Kansas Medical Center
Kansas City, Kansas, United States
RECRUITINGUniversity of Kentucky, Co-Enrolling through ABC-DS Only
Lexington, Kentucky, United States
RECRUITINGMassachusetts General Hospital, Co-Enrolling through ABC-DS Only
Boston, Massachusetts, United States
RECRUITINGWashington University, St. Louis
St Louis, Missouri, United States
RECRUITINGNew York State Institute for Basic Research in Developmental Disabilities (SIBRDD), Co-Enrolling through ABC-DS Only
Staten Island, New York, United States
RECRUITING...and 10 more locations
Enrollment of participants into the Trial-Ready Cohort in DS (TRC-DS).
The primary aim of the TRC-DS is enrollment of 120 participants into the trial ready cohort, with up to 450 participants in total including co-enrollment with the Alzheimer Biomarkers Consortium - Down Syndrome (ABC-DS) study, to support future referral and enrollment into primary Alzheimer's disease (AD) prevention trials for adults with DS.
Time frame: 5 years
Change in cognition as measured by the Cued Recall Test
The Cued Recall Test is modified from a version developed for adults from the typical population. Twelve items are presented for learning, 4 at a time, with each item accompanied by a unique category cue. The testing phase consists of 3 trials. Each trial begins with free recall of the test items; following free recall, a category cue is provided for those items not spontaneously recalled. Two scores are generated from the test, a Free Recall Score and a Total Score (Free Recall plus items recalled when the category cue is provided). A cut-off of \< 23 on the Total Score resulted in a sensitivity of 91% and a specificity of 84% when individuals with DS and a diagnosis of dementia were compared to their healthy peers without dementia.
Time frame: Baseline and Month 32, or until enrollment into a clinical trial
Change in behavior as measured by the Neuropsychiatric Inventory (NPI)
The Neuropsychiatric Inventory (NPI) is a well-validated, reliable, multi-item instrument to assess psychopathology in AD based on an interview with a caregiver or qualified study partner. It evaluates both the frequency and severity of 12 neuropsychiatric features including delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, aberrant motor behavior, sleep, and appetite and eating disorders. A higher NPI score means that the participant is displaying more behavioral symptoms. The minimum score is 0 and the maximum is 144. A score of 0-20 is mild, 20-50 moderate and greater than 50 means significant behavioral symptoms.
Time frame: Screening and Month 32, or until enrollment into a clinical trial
Change in cognition as measured by the Down Syndrome Mental Status Exam (DSMSE)
The DSMSE is an omnibus measure of neuropsychological function that assesses a broad range of skills and is easy to administer. It is divided into items that test recall for personal information, orientation to season and day of week, memory, language, visuospatial function, and praxis. Recall for personal information is tested with questions about the subject's name, age and birth date. Orientation items ask the day of the week and season of the year. Memory in the DSMSE is assessed with items that require immediate and delayed recall of three objects and for the location of three hidden objects. Language items include confrontation naming, sentence repetition, and comprehension of one, two, and three step commands. Visuospatial items are three-dimensional block constructions. Praxis items include transitive and intransitive limb movements and a sequential task.
Time frame: Screening and Month 32, or until enrollment into a clinical trial
Change in behavior as measured by the Vineland 3 (Informant Version)
The Vineland Adaptive Behavior Scale 3 (VABS-II) I is a normed assessment tool that assesses adaptive behavior across the areas of communication, activities of daily living, and socialization. The tool is self-administered via interview toby a study partner using a tablet (e.g. iPad), takes approximately 45 minutes to complete and may be done remotely. The VABS-III scores range from 20-140. Higher scores indicate higher functioning. Specifically, these include 'very high' (domain and Adaptive Behavior Scale (ABC) Standard Scores of 130-140), "moderately high" (domain and ABC Standard Scores of 115-129), "adequate" (domain and ABC Standard Scores of 86-114), "moderately low" (domain and ABC Standard Scores of 71-85), and "low" (domain and ABC Standard Scores of 20-70).
Time frame: Baseline and Month 32, or until enrollment into a clinical trial
Change in cognition as measured by the National Task Group Early Detection Screen for Dementia (NTG-EDSD)
The National Task Group Early Detection Screen for Dementia (NTG-EDSD) is a screening tool which measures changes typically observed in dementia. It is composed of four primary sections about relative demographics, ratings of health, mental health, and life stressors, a review of multiple domains associated with adult functioning, and a review of chronic medical conditions. The NTG-EDSD is completed by a staff member who interviews the caregiver. It contains 40 questions/question groups and takes 15 mins to administer.
Time frame: Baseline and Month 32, or until enrollment into a clinical trial
Change in cognition as measured by the Stroop Dog and Cat Task
In the Stroop Dog and Cat Task, a linear sequence of 16 pictures (8 cats, 8 dogs) are presented in a pre-determined random order. In the control condition the subject says the name of each picture and is urged to do so rapidly. In the experimental (inhibition) condition the participant is required to say 'cat' for the picture of each dog and 'dog' for the cat. For each condition the participant is given a brief practice period. Performance on the Stroop Dog and Cat was significantly related to informant-reported memory changes in 103 adults with DS with mild-moderate intellectual disability in the age range of 36 - 72 years.
Time frame: Baseline and Month 32, or until enrollment into a clinical trial
Change in brain volume as measured by magnetic resonance imaging (MRI)
Time frame: Baseline and Month 32, or until enrollment into a clinical trial
Change in plasma Amyloid Beta (Abeta) biomarkers
Time frame: Baseline and Month 32, or until enrollment into a clinical trial
Change in plasma tau biomarkers
Time frame: Baseline and Month 32, or until enrollment into a clinical trial
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.